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Ivermectin dose assessment without weighing
scales
N.D.E. Alexander,1 S.N. Cousens,2 H. Yahaya,3 A. Abiose,4 & B.R. Jones5
Described are two alternatives to the weighing of patients for assessing the dose of ivermectin for use
in mass chemotherapy campaigns against onchocerciasis. The first method uses height to separate
patients into four dosing categories (1/2, 1, 11/2 and 2 tablets), while the second involves estimating
one of these dosing categories according to an individual's physical appearance, without making any
measurements. Data for the height-based method were obtained from 6373 people who were taking
part in a placebo-controlled trial of ivermectin in northern Nigeria. Use of an arbitrary trade-off of
approximately 100 people "overdosed" for every person "underdosed" would lead to 0.5% of the popula-
tion being underdosed by 1/2 tablet, 46.5% being dosed correctly, 51.7% being overdosed by 1/2 tablet,
and 1.2% being overdosed by 1 tablet. The physical appearance approach involved three observers
and 779 subjects. A total of 82% of the observers' estimates were "correct' with all the incorrect dosing
deviating by only 1/2 tablet from the dose that the subjects should have received.
Introduction
Ivermectin is a microfilaricide that is used in the
treatment of onchocerciasis, a disease from which
about 0.5 million people are blind, mostly in rural
areas of Africa and northem South America. Oncho-
cerciasis is caused by a parasitic worm, Onchocerca
volvulus, and is spread by blackflies of the genus
Simulium; large numbers of microfilariae are found
in the skin and eyes of infected individuals, and
these cause the dermatological and ocular symptoms
that constitute the main burden of the disease. As
described by several workers (1-4) ivermectin
(Mectizan ®, Merck, Sharp & Dohme), a recently
developed drug, is a safe and effective microfilari-
cide. The drug is available in 6-mg tablets, and the
dosing schedule, which is based on 150 gig/kg body
weight, is shown in Table 1.
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Unfortunately, provision of sufficient numbers
of weighing scales to maintain long-term, mass
dosing programmes in the rural areas of developing
countries presents major problems. Although iver-
mectin itself is provided free by the manufacturers,
the cost of the large number of scales needed is sub-
stantial; also, scales can easily lose their calibration
or break completely under field conditions. In prac-
tice, delays in replacing broken or stolen scales
could lead to doses of the drug being administered
haphazardly or to people failing to be dosed at all.
Furthermore, use of standard scales requires basic
literacy skills, and even then confusion may arise if
they are calibrated not only in kg but also in other
units. An alternative method of reliably assessing the
dose of ivermectin is therefore highly desirable.
One candidate measure for this purpose is
height. A height scale could easily be produced by
marking a straight cane or piece of wood in units of
ivermectin tablets. Such canes are cheap and easy to
make and could be distributed widely to all the indi-
viduals entrusted with the dosing. Canes would be
less likely than scales to lose calibration, except pos-
Table 1: Standard dosing schedule for ivermectin,
based on body weight
Patient's weight (kg) No. of 6-mg tablets
<15 0
15-25 1/2
26-44 1
45-64 11/2
>64 2
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sibly through wear of the bottom end, although this
could be reduced by reinforcing the end with metal
from a tin can. The canes would have few uses other
than for dose assessment and so would be less likely
than scales to be stolen; furthermore, health workers
travelling on bicycles could carry measuring tapes
that would enable them to calibrate a measuring cane
in each village.
Use of height as a proxy measure for weight
poses the difficulty that people of the same weight
vary considerably in height, i.e., if dose is assessed
by height many people would be assigned to the
"wrong" dosing category. A trade-off would have to
be made between the number of people "under-
dosed" because they are short for their weight and
the number "overdosed" because they are tall for
their weight. Since ivermectin is safe even at doses
well in excess of the standard schedule (5, 6), we
suggest minimizing the number of people under-
dosed at the cost of overdosing many.
A second alternative to weighing would simply
be to estimate the correct dose on the basis of each
individual's physical appearance. This would have
the advantages of not requiring any equipment and
of allowing some discretion in, for example, dosing
very thin people for whom a rigid height-based
approach would result in too large a dose. On the
other hand, this could lead to incorrect dosing,
depending on the mood of the individual assessing
the dose or because of pressure from those receiving
the drug.
Materials and methods
The subjects for the study were inhabitants of 34
rural communities in Kaduna State, northern Nigeria,
who were participating in a double-blind, placebo-
controlled trial of ivermectin for onchocerciasis,
having given their free and informed consent. Each
individual's dose was assessed, as shown in Table 1,
by weighing the patient on a standard set of house-
hold scales. Height was recorded at the same time,
being read off a vertical scale by placing a flat piece
of wood horizontally on each subject's head. These
measurements were made between December 1988
and October 1989 by a field worker who was a
trained entomology technician.
In December 1991 we investigated the feasibili-
ty of estimating the correct dose of ivermectin, based
on the recipient's physical appearance, using no
equipment. The estimations were performed by two
members of the field team and one local person; all
estimates were made before the patients were weigh-
ed, without knowledge of the correct dose. The pro-
cess was supervised and the data were recorded by
one of the authors (S.N.C.). The two field-team
members were entomology technicians, but had pre-
viously been involved in making anthropometric
measurements, and were asked to use their experien-
ce to estimate the dose for all the people who presen-
ted. The local person was a 28-year-old man who
had been educated to secondary-school level and
worked as a subsistence farmer; such people can be
found in most northern Nigerian villages. He was
chosen because he appeared to be intelligent and was
interested in the study. It was explained to him that
the purpose of the exercise was to determine whether
patients could be dosed correctly with ivermectin
without using a set of scales. He was then told that
there were four dosing categories and that, in gen-
eral, young children received 1/2 tablet, adolescents
1 tablet, most adults 11/2 tablets, and large adults
2 tablets. A few (<10) project staff and onlooking
children were then used as practice subjects before
his estimates for those who presented for dosing
were recorded.
Results
Of the 8230 people who were aged .5 years and
registered in the trial, 6373 (77%) had a pair of
simultaneous weight and height readings available.
Excluded were individuals who were not dosed
because they were ill, pregnant, or underweight, but
the included breast-feeding women, since under cur-
rent criteria these would almost all have been dosed.
The height data, according to standard dosing cate-
gory, are summarized in Table 2 and shown
graphically in Fig. 1. The curves in Fig. 1 can be
used to read off the number of people in any dosing
category whose height was above or below any
given value. For example, there were about 1500
people in the 1 1/2-tablet category with heights <160 cm
and about 250 with heights <150 cm. The num-
ber taller than any given height may be obtained
by subtraction from the total in that category.
Dose assignment by height corresponds to the
three broken perpendiculars shown in Fig. 1 at the
heights chosen as the thresholds between the four
dosing categories.We selected a ratio of overdosings
to underdosing of 100:1, and this leads to the assign-
ments shown in Table 3.
Only 43 people weighed <15 kg, which does not
permit assignment of a height below which no
tablets should be given; all 43 would have received
1/2 tablet according to the criteria in Table 2.
Table 4 compares the assignments according to
the height schedule in Table 3 with those according
to the weight schedule in Table 1.
Use of the height schedule indicates that, rela-
tive to the weight schedule, 34 people would have
been underdosed, 3374 overdosed, and 2965 correct-
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Table 2: Heights of people In the four dosing categories for ivermectin
Height (cm)
25th 75th No. of
No. of tablets Minimum percentile Median percentile Maximum people
0 90 97 99 103 119 43
1/2 92 110 116 123 139 1310
1 109 136 145 151 173 1575
11/2 135 155 160 165 185 3109
2 150 166 170 174 188 336
Overall 90 133 153 162 188 6373
ly dosed. The 34 underdosed would all have received
only 1/2 tablet less than the correct dose. Of the
3374 overdosings, 3298 (98%) would have received
only 1/2 tablet more than the correct dose and the
remaining 76 (2%) just 1 tablet more. The proportion
of the study population who would have received a
dose at most 1/2 tablet greater or less than the correct
dose was 99%.
Table 5 compares the height-based with the
standard weight-based categories in terms of the lat-
ter's original source-the number of jig of ivermec-
tin per kg body weight. The standard categories give
a dose ranging from 231 gg/kg, for a 26-kg indivi-
dual to 120 jig/kg, for someone weighing 75 kg (and
even less for anyone >100 kg). Use of the height-
based categories would result in the vast majority
(98%) of people receiving a dose in the range
100-299 jig/kg. Of the remainder, two individuals
would have received <100 jig/kg (i.e., 97 and 98 jig/
kg) and the rest 300-400 jig/kg.
Fig. 1. Height distribution by dosing category. The
curves show the cumulative height distribution for each
weight-based tablet dosing category. The broken perpendi-
culars show the division of population into height-based
tablet dosing categories.
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The choice of trade-off between underdosing
and overdosing is arbitrary, and Fig. 1 permits inves-
tigation of other thresholds. For example, increasing
the threshold between 1 1/2 and 2 tablets from 158 cm
to 170 cm would mean that virtually no one in the
1-tablet category would receive 2 tablets; this would
nevertheless increase to over 100 the number of
people in the 2-tablet category who are underdosed.
The use of different thresholds for males and
females gave only a minimal increase in perform-
ance. For males the following dosing categories
were used: 1/2 tablet (height, 90-119 cm); 1 tablet
Table 3: Dosing schedule for ivermectin based on
heighta
Patient's height (cm) No. of tablets
90-119 1/2
120-140 1
141-158 11/2
>158 2
a Based on an assignment of approximately 100 overdosings for
every underdosing.
Table 4: Number of people in the standard dosing cate-
gories by weight (see Table 1) compared with those in
the categories based on height
No. of tablets No. of tablets by height
by weight 0 1/2 1 11/2 2 Total
0 0 43 0 0 0 43
1/2 0 781 529 0 0 1310
1 0 6 588 905 76 1575
11/2 0 0 13 1275 1821 3109
2 0 0 0 15 321 336
Total 0 830 1130 2195 2218 6373
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Table 5: Numbers of Individuals according to the dose of ivermectin they would have
received using the standard dosing categories (by weight) and those based on height
No. of individuals
in weight-based
No. of individuals in height-based categories (,ug/kg):
categories (jig/kg) 0-99 100-199 200-299 300-400 Total
0-99 0 0 42 1 43
100-199 2 2628 2850 92 5572
200-299 0 6 720 32 758
300-400 0 0 0 0 0
Total 2 2634 3612 125 6373
(120-144 cm); 1 1/2 tablets (145-162 cm); and 2
tablets (.163 cm). For females the corresponding
categories were: 1/2 tablet (90-119 cm); 1 tablet
(120-138 cm); 1 1/2 tablets (139-155 cm); and 2
tablets (.156 cm). Use of these categories reduced
the number overdosed from 3374 to 3302, the num-
ber underdosed from 34 to 33, while the number cor-
rectly dosed increased from 2965 to 3038. Neverthe-
less, these improvements seem insufficient to
warrant the use of separate threshold values accord-
ing to sex.
Table 6 compares the results obtained by three
observers using the physical appearance method. Of
the two project staff, one (A) correctly estimated the
dose for 272 of 332 people (81.9%), while the other
(B) correctly estimated the dose for 188 of 228
people (82.5%). The local person (C) correctly esti-
mated the dose for 179 of 219 people (81.7%). For
each of the three observers, all of the incorrect esti-
mates deviated only by 1/2 tablet from the correct
dose.
The proportion of correct estimates was much
greater for physical appearance (Table 6) than for
height (Table 4), but the observers were asked to
make their estimates as accurately as possible and to
overdose if in doubt. The best proportion obtained
for correct dosing using height was 81.2%, which is
similar to the levels shown in Table 6. This value
was obtained using the following assignments:
90-128 cm (1/2 tablet); 129-149 cm (1 tablet);
150-181 cm (1 1/2 tablets); and .182 cm (2 tablets).
It should be noted that the populations used to com-
pare the two methods were not identical, since 122
(15.7%) of the 779 individuals shown in Table 6
were not in the placebo-controlled trial, whereas all
those shown in Table 4 were. However, this is un-
likely to invalidate general comparisons between
the two groups.
Discussion
The guidelines for the use of ivermectin are that the
number of tablets given to each person should be
based on the recipient's weight on the day of treat-
ment. However, the practical problems of providing
and maintaining large numbers of weighing scales
mean that weighing everyone is probably not realis-
tic. Our findings show that the vast majority of rural
Africans can be assigned a dose of ivermectin that
deviates by at most 1/2 tablet from the correct dose,
Table 6: Number of individuals in the standard dosing categories (by weight) compared with the numbers in the
categories estimated by two entomology technicians (A and B) and a local person (C)
Estimated number of tablets:
A
1/2 1 1 1/2 2
B
1/2 1 11/2 2
C
1/2 1 1 1/2 2 1/2
Total
I 1 1/2 2
27 15 0 0 27 2 0 0 34 3 0 0 88 20 0
1 83 19 0
0 13 153 4
10 47 11 0
0 8 109 5
0 0 8 9 0 0 4 5
28 111 180 13 37 57 124 10
4 39 13 0
0 3 98 9
15 169 43
0
0
0 24 360 18
0 0 8 8 0 0 20 22
38 45 119 17 103 213 423 40
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either using a set of height-based dosing categories
or based on the individual's physical appearance
without the use of any equipment.
Underdosing is probably more serious than over-
dosing, and our set of height-based categories was
chosen to minimize the number of underdosings.
Less than 1% of our study population would have
been underdosed and <2% would have been over-
dosed by more than 1/2 tablet had our height-based
categories been used. One disadvantage of the
method, however, is that any set of height-based
categories derived from our data might not be appro-
priate in other populations drawn from different
ethnic groups. In addition, the age structure of the
population is relevant, since it affects the proportions
in the various dosing categories. For example, the
majority of people in the 1/2 tablet category would
be dosed correctly using the height criteria, compa-
red with a minority overall. This means that in a
population with fewer children, the height-based
categories will tend to have a lower success rate
(proportion correctly dosed) than we have estimated,
and vice versa. However, the large proportion of
children in our population (24% were aged 5-9
years) is likely to be a feature of most populations
targeted for mass dosing with ivermectin. Using
height to assess the dose of ivermectin will inevi-
tably result in a large number of people being in-
correctly dosed, although, with the cut-off points
we used, almost all of these incorrect dosings
would only have been by a 1/2 tablet.
We also investigated dose assessment based on
the individual's physical appearance alone, without
the use of any equipment. In our sample, around
80% of people assessed in this way would have
received the correct dose, with no incorrect dosings
of more than 1/2 tablet; this compares favourably
with the results obtained using height. The three
observers all achieved very similar success rates,
suggesting that such a rate might be widely obtain-
able by intelligent, motivated staff. On the other
hand, under less well controlled conditions there may
be pressures on the individual dispensing the iver-
mectin to alter the dose, particularly once recipients
see that it varies from person to person. While such
pressure will generally be for overdosing, which is
probably preferable to underdosing, we do not cur-
rently have sufficient data to predict the likely
magnitude and prevalence of incorrect dosings that
might occur if this method were to be applied by
large numbers of staff in a mass campaign.
If ivermectin is to reach, on a regular basis, the
remote rural communities most in need of the drug,
an altemative to using weight as the basis of asses-
sing the dose needs to be found. We have investiga-
ted two altematives, height and physical appearance.
Either of these methods is, in our view, acceptable,
and further research in different populations would
help to clarify which should become the method of
choice.
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Resume
D6termination des doses d'ivermectine
sans balance
L'ivermectine est actuellement le medicament de
choix pour le traitement de l'onchocercose. La
posologie est determinee en fonction du poids
corporel, ce qui necessite l'emploi de balances.
Comme la fourniture de balances pour les pro-
grammes de traitement de masse dans les pays
en d6veloppement pose des problemes financiers
et logistiques, nous avons examin6 deux alterna-
tives a la pesee pour la determination de la dose
d'ivermectine a administrer. 11 est ainsi possible
d'utiliser la taille pour classer les sujets dans les
quatre categories posologiques (1/2, 1, 1 1/2 et 2
comprimes); les categories bas6es sur la taille
permettraient d'utiliser des batons directement
gradu6s en nombre de comprim6s, ce qui consti-
tuerait une solution plus 6conomique, plus facile
d'emploi et plus fiable que les balances. L'autre
possibilit6 serait d'6valuer la dose convenant a
chaque sujet en fonction de son aspect physique,
sans aucun mat6riel.
Pour la m6thode bas6e sur la taille, nous
avons ete amen6s, au vu de donn6es sur le sur-
dosage en ivermectine, a adopter un compromis
permettant de limiter le nombre de sujets "sous-
dos6s", parce que petits pour leur poids, quitte a
"surdoser" de nombreux sujets relativement
grands pour leur poids. Nous avons exp6riment6
cette methode sur 6373 sujets participant a un
essai contre placebo de l'ivermectine dans le nord
du Nigeria. En adoptant une solution de compro-
mis conduisant a surdoser environ 100 sujets
pour un sujet sous-dos6, nous avons conclu que
0,5% des sujets seraient sous-doses d'un demi-
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comprime, 46,5% seraient correctement doses,
51,7% seraient surdoses d'un demi-comprime et
1,2% seraient surdoses d'un comprime. Les cate-
gories de taille proposees sont les suivantes:
90-119cm: 1/2 comprime; 120-140cm: 1 com-
prime; 141-158 cm: 1 1/2 comprime; plus de 158 cm:
2 comprim6s. Dans ces categories, aucun sujet
ne reqoit plus de 400 rg/kg (dose standard:
150 gg/kg). Nous avons tent6 d'etablir des cat6go-
ries de taille differentes pour les hommes et les
femmes, mais I'am6lioration etait negligeable.
En ce qui concerne la methode fondee sur
I'aspect physique du sujet, nos donnees ont ete
fournies par trois observateurs (deux techniciens
en entomologie et un agriculteur local) sur 779
sujets. Au total, 82% des doses estimees etaient
correctes, toutes les doses incorrectes n'etant
fausses que d'un demi-comprim6. Nous pensons
que s'il faut administrer regulierement de l'ivermec-
tine aux communautes rurales recul6es qui en ont
le plus besoin, il faut trouver une methode d'esti-
mation des doses qui ne fasse pas appel a la
pesee. Les deux methodes que nous decrivons
sont, a notre avis, acceptables; chacune a ses
avantages et ses inconvenients. En poursuivant
les essais dans differentes populations, il serait
possible de determiner laquelle devra etre retenue.
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